scholarly journals A LINKING NUMBER DEFINITION OF THE AFFINE INDEX POLYNOMIAL AND APPLICATIONS

2013 ◽  
Vol 22 (12) ◽  
pp. 1341004 ◽  
Author(s):  
LENA C. FOLWACZNY ◽  
LOUIS H. KAUFFMAN
Keyword(s):  
Virtual Knots ◽  
Linking Number ◽  
Linking Numbers ◽  
Vassiliev Invariant ◽  
Definition Of

This paper gives an alternate definition of the Affine Index Polynomial (called the Wriggle Polynomial) using virtual linking numbers and explores applications of this polynomial. In particular, it proves the Cosmetic Crossing Change Conjecture for odd virtual knots and pure virtual knots. It also demonstrates that the polynomial can detect mutations by positive rotation and proves it cannot detect mutations by positive reflection. Finally it exhibits a pair of mutant knots that can be distinguished by a type 2 vassiliev invariant coming from the polynomial.

scholarly journals A POLYNOMIAL INVARIANT OF VIRTUAL LINKS

2013 ◽  
Vol 22 (12) ◽  
pp. 1341002 ◽  
Author(s):  
ZHIYUN CHENG ◽  
HONGZHU GAO
Keyword(s):  
Knot Theory ◽  
Polynomial Invariant ◽  
Polynomial Invariants ◽  
Virtual Knots ◽  
The Third ◽  
Linking Number ◽  
Virtual Links ◽  
Definition Of ◽  
Knots And Links

In this paper, we define some polynomial invariants for virtual knots and links. In the first part we use Manturov's parity axioms [Parity in knot theory, Sb. Math.201 (2010) 693–733] to obtain a new polynomial invariant of virtual knots. This invariant can be regarded as a generalization of the odd writhe polynomial defined by the first author in [A polynomial invariant of virtual knots, preprint (2012), arXiv:math.GT/1202.3850v1]. The relation between this new polynomial invariant and the affine index polynomial [An affine index polynomial invariant of virtual knots, J. Knot Theory Ramification22 (2013) 1340007; A linking number definition of the affine index polynomial and applications, preprint (2012), arXiv:1211.1747v1] is discussed. In the second part we introduce a polynomial invariant for long flat virtual knots. In the third part we define a polynomial invariant for 2-component virtual links. This polynomial invariant can be regarded as a generalization of the linking number.

scholarly journals Cardiovascular disease prevalence in type 2 diabetes – an analysis of a large German statutory health insurance database

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maximilian Gabler ◽  
Silke Geier ◽  
Lukas Mayerhoff ◽  
Wolfgang Rathmann
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Health System ◽  
Cardiovascular Complications ◽  
Population Based ◽  
Stratified Sample ◽  
Icd 10 ◽  
Definition Of ◽  
Observation Period

Abstract Background The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. Methods A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system was used. All patients aged ≥18 years with T2D documented between 1 January 2015 and 31 December 2015 and complete retrospective documentation of ≥5 years (continuous enrollment in the German statutory health system) before 2015 were selected based on a validated algorithm. Cardiovascular disease (CVD) events were identified based on ICD-10 and OPS codes according to a previous clinical study (EMPA-REG OUTCOME trial). Results The prevalence of T2D in Germany in 2015 was 9.9% (n = 324,708). Using a narrow definition of CVD, the 6-year observation period prevalence of CVD was estimated as 46.7% [95% CI: 46.52%;46.86%]. Applying a wider CVD definition, the proportion of T2D patients who showed a history of CVD was 57.1% [95% CI: 56.9%;57.24%]. The prevalence of CVD in patients with T2D ranged from 36.3 to 57.1%, depending on the observation period and definition of CVD. Conclusions The results underline the need for a population-based registration of cardiovascular complications in T2D.

scholarly journals Metabolic Obesity in People with Normal Body Weight (MONW)—Review of Diagnostic Criteria

2022 ◽  
Vol 19 (2) ◽  
pp. 624
Author(s):  
Waldemar Pluta ◽  
Wioleta Dudzińska ◽  
Anna Lubkowska
Keyword(s):  
Body Weight ◽  
Diagnostic Criteria ◽  
Normal Body ◽  
Risk Of Mortality ◽  
Diagnostic Models ◽  
Normal Body Weight ◽  
Definition Of ◽  
The Relationship ◽  
Apparently Healthy

Disorders of metabolic obesity with normal body weight (MONW) are widely recognized risk factors for the development of cardiovascular diseases and type 2 diabetes. Despite this, MONW is not diagnosed in clinical practice. There is no consensus on the definition of MONW, and measuring the degree of insulin resistance or obesity among apparently healthy, non-obese patients is not widely applicable. The awareness of the relationship between metabolic disorders such as MONW and a higher risk of mortality from cardiovascular causes and other related diseases prompts the need for action to be taken aimed at creating appropriate diagnostic models that will allow for the effective detection of those with metabolic abnormalities among people with normal body weight. Such actions are decisive in the prevention and treatment of diseases. Therefore, the purpose of this article is to review the MONW diagnostic criteria used over the years.

scholarly journals Cardiovascular Disease Prevalence in Type 2 Diabetes – An Analysis of A Large German Statutory Health Insurance Database

2020 ◽  
Author(s):  
Maximilian Gabler ◽  
Silke Geier ◽  
Lukas Mayerhoff ◽  
Wolfgang Rathmann
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Health System ◽  
Cardiovascular Complications ◽  
Population Based ◽  
Stratified Sample ◽  
Icd 10 ◽  
Definition Of ◽  
Observation Period

Abstract Background The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. Methods A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system was used. All patients aged ≥ 18 years with T2D documented between 1 January 2015 and 31 December 2015 and complete retrospective documentation of ≥ 5 years (continuous enrollment in the German statutory health system) before 2015 were selected based on a validated algorithm. Cardiovascular disease (CVD) events were identified based on ICD-10 and OPS codes according to a previous clinical study (EMPA-REG OUTCOME trial).Results The prevalence of T2D in Germany in 2015 was 9.9% (n=324,708). Using a narrow definition of CVD, the 6-year observation period prevalence of CVD was estimated as 46.7% [95% CI: 46.52%;46.86%]. Applying a wider CVD definition, the proportion of T2D patients who showed a history of CVD was 57.1% [95% CI: 56.9%;57.24%]. The prevalence of CVD in patients with T2D ranged from 36.3% to 57.1%, depending on the observation period and definition of CVD.Conclusions The results underline the need for a population-based registration of cardiovascular complications in T2D.

Gamification to Promote the Engagement in Healtcare and Wellness of Patients Under Therapeutic Care

2019 ◽  
pp. 244-269 ◽  
Author(s):  
Surendra Prasad Mishra ◽  
Dinkar Kulshreshtha ◽  
Anoop Kumar Srivastava ◽  
Ajeet Kumar Gandhi ◽  
Madhup Rastogi
Keyword(s):  
Virtual Reality ◽  
Smart Phones ◽  
First Century ◽  
Health And Wellness ◽  
Therapeutic Modalities ◽  
Gaming Technology ◽  
Life Threatening ◽  
Physiological Symptoms ◽  
Definition Of

The evolution of gaming in healthcare promotion evolved concurrently with the ascendance of computing technology, smart phones, facilitated by video-based 3D technology and virtual reality in the mid-eighties and nineties. Health and wellness in the twenty-first century is interlinked with the wealth of the nation and individuals and its traditional definition of physical, psychological, spiritual, social, and financial optima has seen new paradigms. The gaming technology has found groundbreaking applications in many diagnostic and therapeutic modalities to modulate the behavioral changes, simulation of virtual reality, and passage to recovery through neurologically engaging the cognitive functions with the stimuli produced. Physiological symptoms and life-threatening disorders which may caused be faced by viral inflictions (HIV, Hepatitis C, etc.) and type 2 diabetes could today be significantly managed by gaming technologies for psychosomatic management.

scholarly journals Depression as a Risk Factor for Dementia and Alzheimer’s Disease

Biomedicines ◽  
2020 ◽  
Vol 8 (11) ◽  
pp. 457 ◽  
Author(s):  
Vanesa Cantón-Habas ◽  
Manuel Rich-Ruiz ◽  
Manuel Romero-Saldaña ◽  
Maria del Pilar Carrera-González
Keyword(s):  
Diabetes Mellitus ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Odds Ratio ◽  
Case Control Study ◽  
Case Control ◽  
Global Deterioration Scale ◽  
Definition Of ◽  
Control Study

Preventing the onset of dementia and Alzheimer’s disease (AD), improving the diagnosis, and slowing the progression of these diseases remain a challenge. The aim of this study was to elucidate the association between depression and dementia/AD and to identify possible relationships between these diseases and different sociodemographic and clinical features. In this regard, a case-control study was conducted in Spain in 2018–2019. The definition of a case was: A person ≥ 65 years old with dementia and/or AD and a score of 5–7 on the Global Deterioration Scale (GDS). The sample consisted of 125 controls; among the cases, 96 had dementia and 74 had AD. The predictor variables were depression, dyslipidemia, type 2 diabetes mellitus, and hypertension. The results showed that depression, diabetes mellitus, and older age were associated with an increased likelihood of developing AD, with an Odds Ratio (OR) of 12.9 (95% confidence interval (CI): 4.3–39.9), 2.8 (95% CI: 1.1–7.1) and 1.15 (95% CI: 1.1–1.2), respectively. Those subjects with treated dyslipidemia were less likely to develop AD (OR 0.47, 95% CI: 0.22–1.1). Therefore, depression and diabetes mellitus increase the risk of dementia, whereas treated dyslipidemia has been shown to reduce this risk.

scholarly journals Diet and Metabolic Syndrome: Where Does Resistant Starch Fit In?

2004 ◽  
Vol 87 (3) ◽  
pp. 756-760 ◽  
Author(s):  
Linda C Tapsell
Keyword(s):  
Metabolic Syndrome ◽  
Heart Disease ◽  
Resistant Starch ◽  
Current Knowledge ◽  
Appetite Control ◽  
Major Health ◽  
Fat Utilization ◽  
The Metabolic Syndrome ◽  
Definition Of

Abstract Metabolic syndrome is a term linking the clinical profiles of some of the world's major health problems today: obesity, heart disease, and diabetes. It is predicated on dietary patterns, and particularly on the delivery of fuel. The effects may be seen first in the development of abdominal obesity and insulin resistance leading to Type 2 diabetes mellitus and coronary heart disease. This review examines the role resistant starch might play in the prevention and management of these conditions. Beginning with a definition of resistant starch, a critical review of the scientific literature is presented. Current knowledge suggests that resistant starch in the diet may assist in the prevention and management of conditions associated with the metabolic syndrome via its potential effects on delaying the delivery of glucose as fuel with subsequent fat utilization and appetite control benefits. There is still a great deal of research to be undertaken in this area, but it is clearly warranted, given the position of starches in the global food supply and the potential impact on population health.

scholarly journals MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Jesper Jensen ◽  
Morten Schou ◽  
Caroline Kistorp ◽  
Jens Faber ◽  
Tine W. Hansen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Ejection Fraction ◽  
Natriuretic Peptides ◽  
Continuous Variable ◽  
Preserved Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Increased Risk ◽  
Definition Of

Abstract Background Mid-regional pro-atrial natriuretic peptide (MR-proANP) is a useful biomarker in outpatients with type 2 diabetes (T2D) to diagnose heart failure (HF). Elevated B-type natriuretic peptides are included in the definition of HF with preserved ejection fraction (HFpEF) but little is known about the prognostic value of including A-type natriuretic peptides (MR-proANP) in the evaluation of patients with T2D. Methods We prospectively evaluated the risk of incident cardiovascular (CV) events in outpatients with T2D (n = 806, mean ± standard deviation age 64 ± 10 years, 65% male, median [interquartile range] duration of diabetes 12 [6–17] years, 17.5% with symptomatic HFpEF) according to MR-proANP levels and stratified according to HF-status including further stratification according to a prespecified cut-off level of MR-proANP. Results A total of 126 CV events occurred (median follow-up 4.8 [4.1–5.3] years). An elevated MR-proANP, with a cut-off of 60 pmol/l or as a continuous variable, was associated with incident CV events (p < 0.001). Compared to patients without HF, patients with HFpEF and high MR-proANP (≥ 60 pmol/l; median 124 [89–202] pmol/l) and patients with HF and reduced ejection fraction (HFrEF) had a higher risk of CV events (multivariable model; hazard ratio (HR) 2.56 [95% CI 1.64–4.00] and 3.32 [1.64–6.74], respectively). Conversely, patients with HFpEF and low MR-proANP (< 60 pmol/l; median 46 [32–56] pmol/l) did not have an increased risk (HR 2.18 [0.78–6.14]). Conclusions Patients with T2D and HFpEF with high MR-proANP levels had an increased risk for CV events compared to patients with HFpEF without elevated MR-proANP and compared to patients without HF, supporting the use of MR-proANP in the definition of HFpEF from a prognostic point-of-view.

Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes

2019 ◽  
Vol 17 (1) ◽  
pp. 87-98
Author(s):  
Muhammad Yazid Jalaludin ◽  
Margarita Barrientos-Pérez ◽  
Mona Hafez ◽  
Jane Lynch ◽  
Naim Shehadeh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Control Group ◽  
Onset Type ◽  
Therapeutic Choice ◽  
Glycemic Targets ◽  
Definition Of

Background The prevalence of type 2 diabetes is increasing in youths and differs from adult-onset type 2 diabetes in its characteristics and progression. Currently, only two drugs are approved for youth-onset type 2 diabetes and many patients are not meeting glycemic targets. Clearly, there is an urgent need to complete clinical trials in youths with type 2 diabetes to increase the therapeutic choice for these patients. However, factors such as limited patient numbers, unwillingness of patients to participate in trials, failure to meet strict inclusion and exclusion criteria, and poor clinic attendance have limited the size and number of trials in this complicated patient demographic. Recommendations This is a narrative opinion piece on the design of clinical trials in youth-onset type 2 diabetes prepared by researchers who undertake this type of study in different countries. The review addresses possible ways to enhance trial designs in youth-onset type 2 diabetes to meet regulatory requirements, while minimizing the barriers to patients’ participation. The definition of adolescence, recruitment of sufficient patient numbers, increasing flexibility in selection criteria, improving convenience of trial visits, requirements of a control group, possible endpoints, and trial compliance are all considered. The authors recommend allowing extrapolation from adult data, using multiple interventional arms within future trials, broadening inclusion criteria, and focusing on endpoints beyond glucose control, among others, in order to improve the successful completion of more trials in this population. Conclusions Improvements in trial design will enable better recruitment and retention and thereby more evidence for treatment outcomes for youth-onset type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document